- Home
- SPOK vs AKBA Comparison
SPOK vs AKBA Comparison
Compare SPOK & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPOK
- AKBA
- Stock Information
- Founded
- SPOK 2004
- AKBA 2007
- Country
- SPOK United States
- AKBA United States
- Employees
- SPOK N/A
- AKBA N/A
- Industry
- SPOK Telecommunications Equipment
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- SPOK Telecommunications
- AKBA Health Care
- Exchange
- SPOK Nasdaq
- AKBA Nasdaq
- Market Cap
- SPOK 329.2M
- AKBA 336.2M
- IPO Year
- SPOK 1992
- AKBA 2014
- Fundamental
- Price
- SPOK $16.43
- AKBA $1.80
- Analyst Decision
- SPOK Hold
- AKBA Strong Buy
- Analyst Count
- SPOK 1
- AKBA 1
- Target Price
- SPOK $15.00
- AKBA $7.50
- AVG Volume (30 Days)
- SPOK 89.0K
- AKBA 1.8M
- Earning Date
- SPOK 02-26-2025
- AKBA 03-13-2025
- Dividend Yield
- SPOK 7.61%
- AKBA N/A
- EPS Growth
- SPOK N/A
- AKBA N/A
- EPS
- SPOK 0.71
- AKBA N/A
- Revenue
- SPOK $137,714,000.00
- AKBA $169,879,000.00
- Revenue This Year
- SPOK $2.45
- AKBA N/A
- Revenue Next Year
- SPOK $0.80
- AKBA $19.31
- P/E Ratio
- SPOK $23.13
- AKBA N/A
- Revenue Growth
- SPOK N/A
- AKBA N/A
- 52 Week Low
- SPOK $13.24
- AKBA $0.80
- 52 Week High
- SPOK $18.14
- AKBA $2.48
- Technical
- Relative Strength Index (RSI)
- SPOK 50.04
- AKBA 28.80
- Support Level
- SPOK $16.25
- AKBA $2.07
- Resistance Level
- SPOK $17.25
- AKBA $2.17
- Average True Range (ATR)
- SPOK 0.33
- AKBA 0.08
- MACD
- SPOK 0.04
- AKBA -0.05
- Stochastic Oscillator
- SPOK 47.10
- AKBA 4.60
About SPOK Spok Holdings Inc.
Spok Holdings Inc is a provider of healthcare communications. It reports three market segments namely Healthcare, Government, and Large enterprise. The company provides paging services and software solutions in the United States and abroad. It provides services such as Value-Added Services, Advisory Services, Assessment Services and Adoption Services.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.